External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
Last updated on July 2021Recruitment
- Recruitment Status
- Enrolling by invitation
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Lung Diseases
- Bronchial Diseases
- Carcinoma
- Carcinoma, Bronchogenic
- RET-fusion Non Small Cell Lung Cancer
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Carcinoma Non-small-cell Lung
- Respiratory Tract Diseases
- Head and Neck Neoplasms
- Lung Neoplasm
- Metastatic Non Small Cell Lung Cancer
- Respiratory Tract Neoplasms
- Neoplasms
- Neoplasms by Histologic Type
- Neoplasms by Site
- Thoracic Neoplasms
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Retrospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04697446
- Collaborators
- Analysis Group, Inc.
- Investigators
- Not Provided
Get Well Soon